Get the Stockscreener App
17.12
1.18%
0.20
After Hours:
17.14
0.02
+0.12%
Amylyx Pharmaceuticals Inc stock is traded at $17.12, with a volume of 816.05K.
It is up +1.18% in the last 24 hours and up +22.37% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$16.92
Open:
$16.93
24h Volume:
816.05K
Relative Volume:
0.67
Market Cap:
$1.89B
Revenue:
$-665.00K
Net Income/Loss:
$-144.74M
P/E Ratio:
-11.03
EPS:
-1.5527
Net Cash Flow:
$-123.48M
1W Performance:
+1.18%
1M Performance:
+22.37%
6M Performance:
+8.42%
1Y Performance:
+341.24%
1-Day Range:
$16.59
$17.16
1-Week Range:
$16.05
$17.36
52-Week Range:
$3.79
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
17.12 | 1.87B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Bull Run: What is Amylyx Pharmaceuticals Incs book value per share2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Layoff Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential - TipRanks
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone - Sahm
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - GuruFocus
Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News - National Today
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 6.9%What's Next? - MarketBeat
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 3.52% on Apr 2 - gurufocus.com
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion - Sahm
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9%Still a Buy? - MarketBeat
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment - Insider Monkey
Buyback Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard) - Stock Titan
Market Recap: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesEarnings Recap Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - za.investing.com
H.C. Wainwright reiterates Amylyx stock rating on trial progress - Investing.com
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):